{"id":1591,"date":"2021-07-14T20:29:54","date_gmt":"2021-07-14T20:29:54","guid":{"rendered":"https:\/\/www.chinaiplawupdate.com\/?p=1591"},"modified":"2021-07-14T20:32:44","modified_gmt":"2021-07-14T20:32:44","slug":"first-generic-declarations-published-on-chinas-new-patent-linkage-system","status":"publish","type":"post","link":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/","title":{"rendered":"First Generic Declarations Published on China’s New Patent Linkage System"},"content":{"rendered":"<p>As of July 13, 2021, four generic declarations have been filed so far on China’s new <a href=\"https:\/\/zldj.cde.org.cn\/home\">patent linkage registration system<\/a>. \u00a0In compliance with the <a href=\"https:\/\/www.chinaiplawupdate.com\/2020\/01\/china-makes-significant-commitments-to-improve-intellectual-property-protection-in-phase-1-trade-deal\/\">Phase One Trade Agreement<\/a>, China implemented a <a href=\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/china-releases-patent-linkage-implementation-measures\/\">patent linkage system<\/a> in their amended patent law effective June 1, 2021. The Chinese patent linkage system prevents marketing approval of generic drugs until after the expiration of patents covering the drugs or uses. The 4 declarations are all from Chinese companies for drugs from Western companies including GlaxoSmithKline (GSK), Novartis and Pfizer.\u00a0<!--more--><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-large wp-image-1592\" src=\"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg\" alt=\"\" width=\"840\" height=\"587\" srcset=\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg 1024w, https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-300x209.jpg 300w, https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-768x536.jpg 768w, https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs.jpg 1162w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><\/p>\n<p>Generics can make the following declarations:<\/p>\n<ol>\n<li>There are no relevant patents registered on the platform;<\/li>\n<li>The relevant patent has lapsed or was declared invalid or the generic applicant has a license;<\/li>\n<li>This is a registered patent but the generic applicant will not sell the drug before expiration of the patent.<\/li>\n<li>There is a registered patent on the platform, but it will be declared invalid or the generic is outside the scope of protection of the patent.<\/li>\n<\/ol>\n<p>The 4 declarations are all from Chinese companies for drugs from Western companies including GlaxoSmithKline (GSK), Novartis and Pfizer. However, only the certification for a Pfizer generic is based on a registered drug (class III) while the other certifications are class I indicating no drug has been registered on the platform (not that there is no relevant drug).\u00a0 These Western companies now have 45 days from publication to either file an <a href=\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/chinas-national-intellectual-property-administration-releases-patent-linkage-administrative-adjudication-measures\/\">administrative adjudication<\/a> with the <a href=\"http:\/\/cnipa.gov.cn\">China National Intellectual Property Administration<\/a> or <a href=\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/chinas-supreme-peoples-court-releases-patent-linkage-trial-provisions\/\">litigation<\/a> with the <a href=\"http:\/\/bjzcfy.chinacourt.gov.cn\/index.shtml\">Beijing Intellectual Property Court<\/a> although GSK and Novartis will need to register their patents first.\u00a0<\/p>\n<p>Within 15 days of receiving a Notice of Acceptance from the Court or CNIPA, the holder must notify the <a href=\"http:\/\/www.cde.org.cn\/\">Center for Drug Evaluation<\/a> (CDE) with a copy of the same or a Notice of Docket and notify the generic drug applicant.\u00a0 The CDE will then impose a 9-month moratorium on marketing authorization approval but will not stop the evaluation of the generic\u2019s application. Note that generics of biologics and TCMs are excluded from the 9-month moratorium. Accordingly, if no decision is reached within 9 months, the generic\u2019s application could be approved shortly thereafter making the speed of the dispute resolution essential.<\/p>\n<figure id=\"attachment_1593\" aria-describedby=\"caption-attachment-1593\" style=\"width: 840px\" class=\"wp-caption alignnone\"><img loading=\"lazy\" decoding=\"async\" class=\"size-large wp-image-1593\" src=\"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/Class3-1024x617.jpg\" alt=\"\" width=\"840\" height=\"506\" srcset=\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/Class3-1024x617.jpg 1024w, https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/Class3-300x181.jpg 300w, https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/Class3-768x463.jpg 768w, https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/Class3.jpg 1098w\" sizes=\"(max-width: 709px) 85vw, (max-width: 909px) 67vw, (max-width: 1362px) 62vw, 840px\" \/><figcaption id=\"caption-attachment-1593\" class=\"wp-caption-text\">This Class 3 declaration lists Pfizer’s patents and relevant claims.<\/figcaption><\/figure>\n<p> <\/p>\n<p><a href=\"#_ednref1\" name=\"_edn1\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p class=\"excerpt\">As of July 13, 2021, four generic declarations have been filed so far on China’s new patent linkage registration system. \u00a0In compliance with the Phase One Trade Agreement, China implemented a patent linkage system in their amended patent law effective June 1, 2021. The Chinese patent linkage system prevents marketing approval of generic drugs until after the expiration of patents covering the drugs or uses. The 4 declarations are all from Chinese companies for drugs from Western companies including GlaxoSmithKline …<\/p>\n<p class=\"more-link\"><a href=\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\" class=\"button\">Continue Reading<\/a><\/p>","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"coauthors":[22],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>First Generic Declarations Published on China's New Patent Linkage System - China IP Law Update<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"First Generic Declarations Published on China's New Patent Linkage System - China IP Law Update\" \/>\n<meta property=\"og:description\" content=\"As of July 13, 2021, four generic declarations have been filed so far on China’s new patent linkage registration system. \u00a0In compliance with the Phase One Trade Agreement, China implemented a patent linkage system in their amended patent law effective June 1, 2021. The Chinese patent linkage system prevents marketing approval of generic drugs until after the expiration of patents covering the drugs or uses. The 4 declarations are all from Chinese companies for drugs from Western companies including GlaxoSmithKline ...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\" \/>\n<meta property=\"og:site_name\" content=\"China IP Law Update\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-14T20:29:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-14T20:32:44+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg\" \/>\n<meta name=\"author\" content=\"Aaron Wininger\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Aaron Wininger\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\"},\"author\":{\"name\":\"Aaron Wininger\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5\"},\"headline\":\"First Generic Declarations Published on China’s New Patent Linkage System\",\"datePublished\":\"2021-07-14T20:29:54+00:00\",\"dateModified\":\"2021-07-14T20:32:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\"},\"wordCount\":380,\"publisher\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg\",\"articleSection\":[\"Patents\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\",\"name\":\"First Generic Declarations Published on China's New Patent Linkage System - China IP Law Update\",\"isPartOf\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage\"},\"thumbnailUrl\":\"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg\",\"datePublished\":\"2021-07-14T20:29:54+00:00\",\"dateModified\":\"2021-07-14T20:32:44+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage\",\"url\":\"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg\",\"contentUrl\":\"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.chinaiplawupdate.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"First Generic Declarations Published on China’s New Patent Linkage System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#website\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/\",\"name\":\"China IP Law Update\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.chinaiplawupdate.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#organization\",\"name\":\"China IP Law Update\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png\",\"contentUrl\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png\",\"width\":240,\"height\":81,\"caption\":\"China IP Law Update\"},\"image\":{\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5\",\"name\":\"Aaron Wininger\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/image\/2a4c57b1fc56e213ed27e140da54c8a1\",\"url\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg\",\"contentUrl\":\"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg\",\"caption\":\"Aaron Wininger\"},\"description\":\"Aaron Wininger is a Principal and Director of the China Intellectual Property at Schwegman Lundberg & Woessner.\",\"sameAs\":[\"http:\/\/www.chinaiplawupdate.com\/aaron-wininger\/\",\"https:\/\/www.linkedin.com\/in\/aaron-wininger-135113\/\"],\"url\":\"https:\/\/www.chinaiplawupdate.com\/author\/aaron-wininger\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"First Generic Declarations Published on China's New Patent Linkage System - China IP Law Update","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/","og_locale":"en_US","og_type":"article","og_title":"First Generic Declarations Published on China's New Patent Linkage System - China IP Law Update","og_description":"As of July 13, 2021, four generic declarations have been filed so far on China’s new patent linkage registration system. \u00a0In compliance with the Phase One Trade Agreement, China implemented a patent linkage system in their amended patent law effective June 1, 2021. The Chinese patent linkage system prevents marketing approval of generic drugs until after the expiration of patents covering the drugs or uses. The 4 declarations are all from Chinese companies for drugs from Western companies including GlaxoSmithKline ...","og_url":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/","og_site_name":"China IP Law Update","article_published_time":"2021-07-14T20:29:54+00:00","article_modified_time":"2021-07-14T20:32:44+00:00","og_image":[{"url":"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg"}],"author":"Aaron Wininger","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Aaron Wininger","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#article","isPartOf":{"@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/"},"author":{"name":"Aaron Wininger","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5"},"headline":"First Generic Declarations Published on China’s New Patent Linkage System","datePublished":"2021-07-14T20:29:54+00:00","dateModified":"2021-07-14T20:32:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/"},"wordCount":380,"publisher":{"@id":"https:\/\/www.chinaiplawupdate.com\/#organization"},"image":{"@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage"},"thumbnailUrl":"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg","articleSection":["Patents"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/","url":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/","name":"First Generic Declarations Published on China's New Patent Linkage System - China IP Law Update","isPartOf":{"@id":"https:\/\/www.chinaiplawupdate.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage"},"image":{"@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage"},"thumbnailUrl":"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg","datePublished":"2021-07-14T20:29:54+00:00","dateModified":"2021-07-14T20:32:44+00:00","breadcrumb":{"@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#primaryimage","url":"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg","contentUrl":"http:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2021\/07\/FirstFourDecs-1024x715.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.chinaiplawupdate.com\/2021\/07\/first-generic-declarations-published-on-chinas-new-patent-linkage-system\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.chinaiplawupdate.com\/"},{"@type":"ListItem","position":2,"name":"First Generic Declarations Published on China’s New Patent Linkage System"}]},{"@type":"WebSite","@id":"https:\/\/www.chinaiplawupdate.com\/#website","url":"https:\/\/www.chinaiplawupdate.com\/","name":"China IP Law Update","description":"","publisher":{"@id":"https:\/\/www.chinaiplawupdate.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.chinaiplawupdate.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.chinaiplawupdate.com\/#organization","name":"China IP Law Update","url":"https:\/\/www.chinaiplawupdate.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png","contentUrl":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/cropped-China-IP-Law-Update-Logo-for-website-1.png","width":240,"height":81,"caption":"China IP Law Update"},"image":{"@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/cd3c63c8dfee9e4c102809b921868bc5","name":"Aaron Wininger","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.chinaiplawupdate.com\/#\/schema\/person\/image\/2a4c57b1fc56e213ed27e140da54c8a1","url":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg","contentUrl":"https:\/\/www.chinaiplawupdate.com\/wp-content\/uploads\/2019\/07\/China-IP-Law-Blog-Square-96x96.jpg","caption":"Aaron Wininger"},"description":"Aaron Wininger is a Principal and Director of the China Intellectual Property at Schwegman Lundberg & Woessner.","sameAs":["http:\/\/www.chinaiplawupdate.com\/aaron-wininger\/","https:\/\/www.linkedin.com\/in\/aaron-wininger-135113\/"],"url":"https:\/\/www.chinaiplawupdate.com\/author\/aaron-wininger\/"}]}},"co_authors":[4],"_links":{"self":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts\/1591"}],"collection":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/comments?post=1591"}],"version-history":[{"count":2,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts\/1591\/revisions"}],"predecessor-version":[{"id":1595,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/posts\/1591\/revisions\/1595"}],"wp:attachment":[{"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/media?parent=1591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/categories?post=1591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/tags?post=1591"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.chinaiplawupdate.com\/wp-json\/wp\/v2\/coauthors?post=1591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}